News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2015 Archives

Dec 21, 2015
- Topline results find no inhibitors to ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], treatment were reported and nearly 73 percent of treated patients experienced zero joint bleeds

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced...

More
Dec 8, 2015

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual Healthcare Conference to be held at The Westin New...

More
Dec 8, 2015

Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors....

More
Dec 7, 2015
- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is built on ADVATE [Antihemophilic Factor (Recombinant)], offering proven bleed protection with a simple, twice-weekly dosing schedule

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has showcased...

More
Nov 30, 2015
- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], approved by the FDA in November, is built on ADVATE [Antihemophilic Factor (Recombinant)], which been used by Hemophilia A patients worldwide for more than 12 years

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved medical conditions, today...

More
Nov 17, 2015

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies Autumn 2015 Global Healthcare Conference to be held at the May...

More
Nov 16, 2015
- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is built on ADVATE [Antihemophilic Factor (Recombinant)], a well-established treatment for hemophilia A patients with more than 12 years of patient experience

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today...

More
Nov 5, 2015

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2015. Cash and investments in marketable securities at September 30, 2015 were...

More
Oct 29, 2015

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2015 on Thursday, November 5, 2015, after the close of U.S.-based financial...

More
Oct 8, 2015

Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the Company's pain and oncology portfolio during an Investor and Analyst R&D Day being hosted today from 12:30 - 3:30 p.m. Eastern...

More
Oct 7, 2015

Nektar Therapeutics (NASDAQ:NKTR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NKTR-214, its lead...

More
Oct 6, 2015

Nektar Therapeutics (Nasdaq: NKTR) today announced the closing of a direct private placement of $250 million of 7.75% Senior Secured Notes Due in 2020 with investment vehicles managed by...

More
Oct 1, 2015

Nektar Therapeutics (NASDAQ: NKTR) today announced that it will host a Research and Development (R&D) Day for analysts and investors on Thursday, October 8, 2015. The event is scheduled to take...

More
Sep 21, 2015

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of...

More
Sep 1, 2015

Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial...

More
Aug 5, 2015

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2015. Cash and investments in marketable securities at June 30, 2015 were $279.7...

More
Jul 29, 2015

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2015 on Wednesday, August 5, 2015, after the close of U.S.-based financial markets....

More
Jul 16, 2015
- Twice-weekly prophylactic regimen with the investigational, extended half-life recombinant factor VIII resulted in 95 percent reduction in median annualized bleed rate compared to on-demand treatment

DEERFIELD, Ill., July 16, 2015 – Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and...

More
Jun 2, 2015
New collaboration to include translational research into predictive biomarkers

Nektar Therapeutics (NASDAQ:NKTR) and The University of Texas MD Anderson Cancer Center today announced a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214, a...

More
May 28, 2015

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2015 Global Healthcare Conference in New York City on...

More
Apr 30, 2015

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2015. Cash and investments in marketable securities at March 31, 2015 were $325.8...

More
Apr 23, 2015

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015, after the close of U.S.-based financial markets....

More
Apr 16, 2015

Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour...

More
Apr 13, 2015

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the 14th Annual Needham Healthcare Conference to be held at the Westin Grand...

More
Apr 2, 2015
Cash Payment Resulting from First Commercial Sale of MOVANTIK™ (naloxegol) Tablets in the US

Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The cash payment under the Nektar-AstraZeneca agreement...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide